Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...

The dyad model fosters collaboration between academic specialists and community oncologists, ensuring seamless patient care ...

Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...

Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...

With the debut of TrumpRx.gov and other moves, the administration is steering the nation toward a market-driven, “America ...

Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care ...

Ever-smokers receiving immunotherapy for gastric and esophageal cancers showed better survival outcomes but higher relapse ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...